Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2023 02:00 ET | Source: Addex Therapeutics

Addex Announces Participation in the Bio-Europe 2023 Conference

Geneva, Switzerland, November 2, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
October 20, 2023 01:00 ET | Source: Addex Therapeutics

Addex Completes ADS Ratio Change

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
October 06, 2023 16:00 ET | Source: Addex Therapeutics

Addex Announces Plan to Implement ADS Ratio Change

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
September 20, 2023 01:00 ET | Source: Addex Therapeutics

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

Addex led consortium wins Eurostars grant to deliver clinical candidates to treat mild neurocognitive disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 20, 2023 -...
September 06, 2023 01:00 ET | Source: Addex Therapeutics

Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
September 05, 2023 01:00 ET | Source: Addex Therapeutics

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...
September 04, 2023 01:00 ET | Source: Addex Therapeutics

Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain

Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functionsFirst time mGlu5 linked to post-stroke functional recovery Ad Hoc Announcement Pursuant to...
August 10, 2023 01:00 ET | Source: Addex Therapeutics

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendationIndivior GABAB PAM collaboration extended to June 2024...
August 04, 2023 01:00 ET | Source: Addex Therapeutics

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

Geneva, Switzerland, August 3, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
August 03, 2023 01:00 ET | Source: Addex Therapeutics

Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration

Discovery collaboration on track to deliver clinical candidates for IND enabling studies in 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 3, 2023 - Addex...